drugset / Trial / NCT05199077
A Study of GM-XANTHO in Pressure Ulcer Patients
Phase 2
Not yet recruiting
58 enrolled
Xantho Biotechnology Co., LTD
Virginia Contract Research Organization Co., Ltd. · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a randomized, placebo-controlled, double-blind, 3-arm, single-center, phase IIa, parallel study to assess the efficacy, safety, and tolerability of topically applied 2.5%, 5% GM-XANTHO plus standard of care in patients with stage II or stage III pressure ulcer.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2028-12-31
- Completion
- 2029-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | GM-XANTHO | Unknown | 2.5 % | Topical |
| Comparator | GM-XANTHO | Unknown | 5 % | Topical |